Isomalto oligosaccharide sulfate inhibits tumor growth and metastasis of hepatocellular carcinoma in nude mice

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Xiao, Chun Li ^a   Tao, Zhong Hua ^a   Guo, Lin ^a   Li, Wei Wei ^a   Wan, Jin Liang ^a   Sun, Hui Chuan ^a   Wang, Lu ^a   Tang, Zhao You ^a   Fan, Jia ^a   Wu, Wei Zhong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

apoptosis; Isomalto oligosaccharide sulfatehepatocellular carcinomaproliferationmetastasis

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLINE; GENE PRODUCT; ISOMALTOOLIGOSACCHARIDE SULFATE; MITOGEN ACTIVATED PROTEIN KINASE; OLIGOSACCHARIDE; PROTEIN BAI 1; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN PRC1; PROTEIN REPRIMO; PROTEIN TP73; RED FLUORESCENT PROTEIN; SCATTER FACTOR RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BEL 7402 CELL; BODY WEIGHT; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CELL ASSAY; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL INVASION; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETIC SCREENING; GROWTH CURVE; HEART; HEP3B CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY FUNCTION; KIDNEY PARENCHYMA; LIVER; LIVER CELL CARCINOMA; LIVER FUNCTION; LUNG METASTASIS; MAXIMUM TOLERATED DOSE; MESENTERY METASTASIS; METASTASIS; METASTASIS INHIBITION; MORTALITY; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE COUNT; TRANSWELL ASSAY; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE; CELL MOTION; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; MALE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGOSACCHARIDES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79954997182     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-150     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917. 10.1016/S0140-6736(03)14964-1, 14667750.
3. Seong J. Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med J 2009, 50:601-612. 10.3349/ymj.2009.50.5.601, 2768232, 19881961.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236. 10.1002/hep.20933, 16250051.
5. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, . EASL Panel of Experts on HCC Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430. 10.1016/S0168-8278(01)00130-1, 11592607, EASL Panel of Experts on HCC.
6. Goldshmidt O, Zcharia E, Abramovitch R, Metzger S, Aingorn H, Friedmann Y, Schirrmacher V, Mitrani E, Vlodavsky. Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci USA 2002, 99:10031-10036. 10.1073/pnas.152070599, 126619, 12097647.
7. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 1999, 5:803-809. 10.1038/10525, 10395326.
8. Toyoshima M, Nakajima M. Human heparanase purification, characterization, cloning, and expression. J Biol Chem 1999, 274:24153-24160. 10.1074/jbc.274.34.24153, 10446189.
9. Vlodavsky I, Miao HQ, Medalion B, Danagher P, Ron D. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 1996, 15:177-186. 10.1007/BF00437470, 8842489.
10. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998, 49:407-424. 10.1146/annurev.med.49.1.407, 9509272.
11. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999, 59:3433-3441.
12. Zhao H, Liu H, Chen Y, Xin X, Li J, Hou Y, Zhang Z, Zhang X, Xie C, Geng M, Ding J. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis. Cancer Res 2006, 66:8779-8787. 10.1158/0008-5472.CAN-06-1382, 16951194.
13. Basche M, Gustafson DL, Holden SN, O'Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 2006, 12:5471-5480. 10.1158/1078-0432.CCR-05-2423, 17000682.
14. Chow LQ, Gustafson DL, O'Bryant CL, Gore L, Basche M, Holden SN, Morrow MC, Grolnic S, Creese BR, Roberts KL, Davis K, Addison R, Eckhardt SG. A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol 2008, 63:65-74. 10.1007/s00280-008-0712-z, 2813677, 18320191.
15. Lewis KD, Robinson WA, Millward MJ, Powell A, Price TJ, Thomson DB, Walpole ET, Haydon AM, Creese BR, Roberts KL, Zalcberg JR, Gonzalez R. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs 2008, 26:89-94. 10.1007/s10637-007-9080-5, 17891338.
16. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Lee CC, Yu MC, Hu RH, Peng CY, Lai KL, Chang SS, Chen PJ. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009, 50:958-968. 10.1016/j.jhep.2008.12.023, 19303160.
17. Yang BW, Liang Y, Xia JL, Sun HC, Wang L, Zhang JB, Tang ZY, Liu KD, Chen J, Xue Q, Chen J, Gao DM, Wu WZ. Biological characteristics of fluorescent protein-expressing human hepatocellular carcinoma xenograft model in nude mice. Eur J Gastroenterol Hepatol 2008, 20:1077-1084. 10.1097/MEG.0b013e3283050a67, 19047839.
18. Sun FX, Tang ZY, Lui KD, Ye SL, Xue Q, Gao DM, Ma ZC. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer 1996, 66:239-243. 10.1002/(SICI)1097-0215(19960410)66:2<239::AID-IJC17>3.0.CO;2-7, 8603818.
19. Xiong W, Ren ZG, Qiu SJ, Sun HC, Wang L, Liu BB, Li QS, Zhang W, Zhu XD, Liu L, Wang WQ, Tang ZY. Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin. BMC Cancer 2010, 10:219-229. 10.1186/1471-2407-10-219, 2880993, 20487542.
20. Zhuang PY, Zhang JB, Zhang W, Zhu XD, Liang Y, Xu HX, Xiong YQ, Kong LQ, Wang L, Wu WZ, Tang ZY, Qin LX, Sun HC. Long-term interferon-α treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma. J Cancer Res Clin Oncol 2010, 136:1891-1900. 10.1007/s00432-010-0848-1, 20213095.
21. Cole CL, Jayson GC. Oligosaccharides as anti-angiogenic agents. Expert Opin Biol Ther 2008, 8:351-362. 10.1517/14712598.8.3.351, 18294105.
22. Kuribayashi K, El-Deiry WS. Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol 2008, 615:201-221. 10.1007/978-1-4020-6554-5_10, 18441595.
23. Mori E, Takahashi A, Yamakawa N, Kirita T, Ohnishi T. High LET heavy Ion radiation induces p53-independent apoptosis. J Radiat Res 2009, 50:37-42. 10.1269/jrr.08075, 18957831.
24. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci 2003, 116:4077-4085. 10.1242/jcs.00739, 12972501.
25. Qin LX, Tang ZY, Liu KD. p53 mutations may be related to tumor invasiveness of human hepatocellular carcinoma in China. Oncol Rep 1995, 2:1175-1179.
26. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepato- cellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007, 26:2166-2176. 10.1038/sj.onc.1210279, 17401425.
27. Seo DW, Chen Q, Smith ML, Zarnegar R. Regulation of the c-met Proto-oncogene Promoter by p53. J Biol Chem 1999, 274:3565-3572. 10.1074/jbc.274.6.3565, 9920903.
28. Hemann MT, Lowe SW, . The p53-Bcl-2 connection Cell Death Differ. 2006, 13:1256-1259. The p53-Bcl-2 connection.
29. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002, 21:2613-2622. 10.1038/sj.onc.1205353, 11965534.
30. Duda DG, Sunamura M, Lozonschi L, Yokoyama T, Yatsuoka T, Motoi F, Horii A, Tani K, Asano S, Nakamura Y, Matsuno S. Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis. Br J Cancer 2002, 86:490-496. 10.1038/sj.bjc.6600067, 2375213, 11875720.
31. He X, Wei C, Song T, Yuan J, Zhang Y, Ma Q, Shi W, Zhong H. Proliferating cell nuclear antigen destabilizes c-Abl tyrosine kinase and regulates cell apoptosis in response to DNA damage. Apoptosis 2009, 14:268-275. 10.1007/s10495-009-0313-2, 19156526.
32. Castellino RC, De Bortoli M, Lin LL, Skapura DG, Rajan JA, Adesina AM, Perlaky L, Irwin MS, Kim JY. Overexpressed TP73 induces apoptosis in medulloblastoma. BMC Cancer 2007, 7:127-142. 10.1186/1471-2407-7-127, 1955450, 17626635.